<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>263773</rcn>
  <id>101163492</id>
  <acronym>ApTOLL</acronym>
  <teaser><![CDATA[Stroke is a devastating medical condition affecting 15 million people worldwide yearly, being Ischemic Stroke the most frequent (87%). Indeed, the global cost of stroke is >847b (60b in EU) due to the huge socioeconomic burden of disabilities. Reperfusion treatment improves...]]></teaser>
  <objective><![CDATA[Stroke is a devastating medical condition affecting 15 million people worldwide yearly, being Ischemic Stroke the most frequent (87%). Indeed, the global cost of stroke is >847b (60b in EU) due to the huge socioeconomic burden of disabilities. Reperfusion treatment improves outcomes, but only 20% of patients are currently eligible for treatment due to the narrow therapeutic window after stroke symptom onset and stringent selection criteria for eligibility. Novel therapies - small molecules or biologics - targeting neuroprotection have not achieved enough efficacy to get approved. 
aptaTargets has successfully developed ApTOLL, an immune modulator and neuroprotectant with a novel approach TO REDUCE BRAIN DAMAGE in AIS patients. aptaTargets ApTOLL drug has a novel approach targeting TLR4 to reduce brain damage in acute ischemic stroke (AIS) patients (47% reduction of FIV), reduce mortality from 18% to 4% and improve functional outcomes. Due to the innovative MODE OF ACTION AND NATURE of the molecule (an aptamer), ApTOLL represents a novel and disruptive approach to treating stroke in the first hours after the onset (acute phase), substantially reducing brain damage and improving Quality of Life (QoL) in short and long time.
ApTOLL is targeting the Multi-Billion Market of the global Stroke Management Market, valued at 31.7Bn in 2020 and expected to reach 67.7Bn in 2030 (7.8% CAGR). As a first indication within the scope of this EIC Accelerator proposal, ApTOLL will target AIS patients (87%) who received EVT therapy, expecting to be potentially used as neuroprotectant in all stroke patients, based on preclinical and clinical results. 
The EIC project aims to conduct the Ph2b trial of ApTOLL and demonstrate its efficacy before entering Ph3. It will boost our chances of licencing the product to a pharma company, increasing the value of the agreement.]]></objective>
  <title>ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)</title>
  <keywords>Acute ischemic stroke, neuroprotection, aptamer, therapy, TLR4 receptor, brain damage,clinical trial, Stroke, ApTOLL, inflammation, oligonucleotides, neurology, neurovascular, drug development, health</keywords>
  <totalCost>3569737.25</totalCost>
  <ecMaxContribution>2498816</ecMaxContribution>
  <startDate>2024-01-01</startDate>
  <endDate>2026-03-31</endDate>
  <ecSignatureDate>2024-05-20</ecSignatureDate>
  <duration>27</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101163492</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate readOnly="true">2024-05-27 11:07:01</contentCreationDate>
  <contentUpdateDate>2024-05-27 11:06:46</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-11-03 09:43:49</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="2498816" terminated="false" sme="true" netEcContribution="2498816" totalCost="3569737.25" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1984332</rcn>
        <id>903362359</id>
        <vatNumber>ESB87154118</vatNumber>
        <legalName>APTATARGETS SL</legalName>
        <address>
          <street>AVDA CARDENAL HERRERA ORIA 298 - 1 PLANTA DESPACHO 4</street>
          <city>MADRID</city>
          <postalCode>28035</postalCode>
          <country>ES</country>
          <geolocation>40.5248319,-3.7715627754518115</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Madrid</name>
              <rcn>242233344</rcn>
              <nutsCode>ES300</nutsCode>
              <parents>
                <region>
                  <name>Comunidad de Madrid</name>
                  <rcn>242233384</rcn>
                  <nutsCode>ES30</nutsCode>
                  <parents>
                    <region>
                      <name>Comunidad de Madrid</name>
                      <rcn>242235944</rcn>
                      <nutsCode>ES3</nutsCode>
                      <parents>
                        <region>
                          <name>Spain</name>
                          <rcn>242387496</rcn>
                          <nutsCode>ES</nutsCode>
                          <euCode>ES</euCode>
                          <isoCode>ES</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>707276</rcn>
        <id>HORIZON_HORIZON-EIC-2023-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2023-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2023</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1317821</rcn>
        <id>101163492_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - ApTOLL (ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS))</title>
        <teaser><![CDATA[Stroke is a devastating medical condition affecting 15 million people worldwide yearly, being Ischemic Stroke the most frequent (87%). Indeed, the global cost of stroke is >€847b (≈€60b in EU) due to the huge socioeconomic burden of disabilities. Reperfusion treatment...]]></teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-06-11 22:15:29</sourceUpdateDate>
        <contentUpdateDate>2025-06-11 22:15:29</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101163/101163492_PS/imagen1-aptatarget-rp1.jpg</uri>
              <alternativeText>AptaTargets team at International Stroke Conference 2025, Los Angeles (USA).</alternativeText>
              <mimetype readOnly="true">image/jpeg</mimetype>
              <size readOnly="true">122880</size>
            </webItem>
          </associations>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/29/101/553/1353</code>
        <title>mortality</title>
        <displayCode readOnly="true">/social sciences/sociology/demography/mortality</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/153/635</code>
        <title>stroke</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/neurology/stroke</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode readOnly="true">/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
